NVRO - Nevro Corp.About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $165.91 | Open | $165.55 |
| Volume | 391.9K | Market Cap | 5.794B |
| Yield | Last Dividend |
| Nevro Reports Fourth Quarter and Full Ye... | 4:05 PM |
| REDWOOD CITY, Calif., Feb. 24, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Nevro to Present at Citi's 2021 Healthca... | 02/01/21 |
| REDWOOD CITY, Calif., Feb. 1, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-ba... | |
| Nevro to Report Fourth Quarter and Full-... | 01/27/21 |
| REDWOOD CITY, Calif., Jan. 27, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Clinical Data Presented at 2021 North Am... | 01/19/21 |
| REDWOOD CITY, Calif., Jan. 19, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Nevro to Highlight New Clinical Evidence... | 01/14/21 |
| REDWOOD CITY, Calif., Jan. 14, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Nevro Announces Preliminary, Unaudited F... | 01/11/21 |
| REDWOOD CITY, Calif., Jan. 11, 2021 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Spinal Cord Stimulator Market to Witness... | 01/08/21 |
| ReportsnReports.com the exclusive leading provider of market research reports published research report on ???Global Spinal Cord Stimulator Market Res... | |
| Boston Scientific Announces Stipulation ... | 12/14/20 |
| /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that a stipulation of dismissal has been filed in the Nevro Corporation (NYS... | |
| Nevro Announces Agreement to Conclude It... | 12/14/20 |
| /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of ... | |
| Neurostimulation Devices Market Opportun... | 12/08/20 |
| Global Neurostimulation Devices Market Analysis to 2025 is a specialized and in-depth study of the Neurostimulation Devices industry with a focus on t... | |
| Nevro Announces Director Appointment | 12/03/20 |
| REDWOOD CITY, Calif., Dec. 3, 2020 /PRNewswire/ -- Nevro Corp. ("Nevro") (NYSE: NVRO), a global medical device company that is providing innovative, e... | |
| ??Nevro to Participate in Citi Bank Head... | 11/24/20 |
| REDWOOD CITY, Calif., Nov. 24, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Nevro (NYSE:NVRO) Upgraded by TheStreet ... | 11/20/20 |
| TheStreet upgraded shares of Nevro (NYSE:NVRO) from a d+ rating to a c- rating in a research report released on Wednesday, TheStreetRatingsTable repor... | |
| Nerve Stimulator Market With Leading Pla... | 11/19/20 |
| The electrical nerve stimulation procedure uses a nerve stimulator, which treats chronic pain with an electrical current. A nerve stimulator set at lo... | |
| Nevro Announces Abstract Presentations f... | 11/17/20 |
| REDWOOD CITY, Calif., Nov. 17, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Nevro Announces Third Quarter 2020 Finan... | 11/05/20 |
| REDWOOD CITY, Calif., Nov. 5, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-ba... | |
| Nevro Earnings Scorecard & Analyst Repor... | 11/05/20 |
| Nevro announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by??? | |
| Neurostimulation Devices Market Top Key ... | 10/27/20 |
| Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the... | |
| Neurostimulation Devices Market Top Key ... | 10/27/20 |
| Summary of the Neurostimulation Devices Market Report Due to the various economic, technological, research & development and geographical aspects, the... | |
| Nevro (NYSE:NVRO) Raised to ???Positive?... | 10/24/20 |
| OTR Global upgraded shares of Nevro (NYSE:NVRO) to a positive rating in a research report report published on Wednesday morning, The Fly reports. Seve... | |
| The Daily Biotech Pulse: Gilead Gets Ful... | 10/23/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22) Ami... | |
| Nevro to Report Third Quarter 2020 Finan... | 10/22/20 |
| REDWOOD CITY, Calif., Oct. 22, 2020 /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-b... | |
| Nevro (NYSE:NVRO) Upgraded to ???Positiv... | 10/22/20 |
| OTR Global upgraded shares of Nevro (NYSE:NVRO) to a positive rating in a research note released on Wednesday, The Fly reports. Several other equities... | |
| Neurosurgery Devices Market Expected to ... | 10/22/20 |
| Rise in incidences and prevalence of neurological conditions within the population and the advantage of neurosurgery over other conventional surgeries... | |
| Analysts Anticipate Nevro Corp. (NYSE:NV... | 10/20/20 |
| Equities research analysts predict that Nevro Corp. (NYSE:NVRO) will announce $103.56 million in sales for the current quarter, Zacks Investment Resea... | |
| Zacks: Brokerages Expect Nevro Corp. (NY... | 10/20/20 |
| Brokerages predict that Nevro Corp. (NYSE:NVRO) will report earnings per share (EPS) of ($0.58) for the current quarter, according to Zacks. Six analy... | |
| Liberty All-Star?? Growth Fund, Inc. Sep... | 10/15/20 |
| BOSTON , Oct. 15, 2020 /PRNewswire/ -- Below is the September 2020 Monthly Update for the Liberty All-Star Growth Fund, Inc. (NYSE: ASG ) Liberty All-... | |
| The Daily Biotech Pulse: Vertex Pulls Pl... | 10/15/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 14) 10X... | |
| The Daily Biotech Pulse: J&J Pauses Coro... | 10/13/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 12) 10X... | |
| Implantable Neurostimulators Market Size... | 10/13/20 |
| SAN FRANCISCO , Oct. 13, 2020 /PRNewswire/ -- The global implantable neurostimulators market size is anticipated to reach USD 11.0 billion by 2027, ex... | |
| Strong Buy rating | 02/02/21 |
| Piper Sandler initiates coverage with Overweight rating and announces Price Target of $190.00 | |
| Strong Buy rating | 01/19/21 |
| SVB Leerink maintains Outperform rating and raises Price Target from $190.00 to $210.00 | |
| Strong Buy rating | 12/15/20 |
| Morgan Stanley maintains Overweight rating and raises Price Target from $161.00 to $192.00 | |
| Date | Today (AMC) | Est. (EPS/Rev.) | ($0.33)/ 107.43M |
| Actual (EPS/Rev.) | $-0.21/ $109.73 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Potential Trading Ideas | Potential Trading | 59.00 % | Follow |
| Optioneering-W | Sam Allen | 27.00 % | Follow |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
